Can Utah Medicaid deny coverage for experimental medical treatments? Peterson v. Utah Department of Health Explained

In Peterson v. Utah Department of Health, the Utah Court of Appeals addressed whether Medicaid must cover experimental medical treatments when a physician deems them medically necessary. The case involved a two-year-old child with short bowel syndrome whose mother sought coverage for off-label growth hormone therapy.

Background and Facts

Markelle Frei-Peterson suffered from short bowel syndrome and relied on intravenous feeding. Her treating physician recommended growth hormone treatment to improve nutrient absorption, though this constituted an off-label use not approved by the FDA for this condition. After three months of charitable funding showed some improvement, the family sought Medicaid coverage. The Utah Department of Health’s Drug Utilization Review Board denied the request, classifying the treatment as experimental under Utah Administrative Code Rule 414-10-5(4), which excludes “experimental or medically unproven physician services or procedures” from coverage.

Key Legal Issues

The central issue was whether DHCF properly determined that growth hormone treatment for short bowel syndrome constituted an experimental procedure under Utah’s Medicaid guidelines. The case required interpreting Utah’s definition of “experimental or unproven medical practice” and determining what evidence establishes that a treatment is “widely utilized as a standard medical practice.”

Court’s Analysis and Holding

The court applied a substantial evidence standard to the agency’s factual findings while noting that some deference was owed to DHCF’s medical expertise. Drawing on federal precedent from Rush v. Parham, the court distinguished between treatments that are “rarely used, novel or relatively unknown” versus those “generally accepted by the professional medical community as an effective and proven treatment.” The court found that the physician’s own ambivalent testimony about the treatment’s effectiveness, combined with limited supporting literature from a single four-week study, constituted substantial evidence that the treatment remained experimental. Notably, the treating physician admitted the treatment “could be disproved” and acknowledged controversy surrounding its use.

Practice Implications

This decision establishes that Utah agencies may reasonably limit Medicaid coverage by excluding experimental treatments, even when a physician deems them medically necessary. The ruling clarifies that “authoritative evidence” of safety and effectiveness is required to overcome an experimental classification. For practitioners challenging such denials, the decision emphasizes the need for robust evidence demonstrating widespread acceptance and proven efficacy within the medical community, not merely isolated studies or individual physician opinions.